MAPK3 and cancer: To test whether activation of the ERK1/2 pathway contributes to the cancer promoting effect of the SASP, we treated MCF7 and ZR-75 cells with the MEK1/2 inhibitor U0126 (or vehicle) together with CM from non-senescent or senescent cells.